Literature DB >> 16258545

Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency.

Volker Patzel1, Sascha Rutz, Isabell Dietrich, Christian Köberle, Alexander Scheffold, Stefan H E Kaufmann.   

Abstract

In RNA interference (RNAi), guide RNAs direct RNA-induced silencing complexes (RISC) to their mRNA targets, thus enabling the cleavage that leads to gene silencing. We describe a strong inverse correlation between the degree of guide-RNA secondary structure formation and gene silencing by small interfering (si)RNA. Unstructured guide strands mediate the strongest silencing whereas structures with base-paired ends are inactive. Thus, the availability of terminal nucleotides within guide structures determines the strength of silencing. A to G and C to U base exchanges, which involve wobble base-pairing with the target but preserve complementarity, turned inactive into active guide structures, thereby expanding the space of functional siRNAs. Previously observed base degenerations among mature micro (mi)RNAs together with the data presented here suggest a crucial role of the guide-RNA structures in miRNA action. The analysis of the effect of the secondary structures of guide-RNA sequences on RNAi efficiency provides a basis for better understanding RNA silencing pathways and improving the design of siRNAs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258545     DOI: 10.1038/nbt1151

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  49 in total

1.  Rab3-interacting molecule gamma isoforms lacking the Rab3-binding domain induce long lasting currents but block neurotransmitter vesicle anchoring in voltage-dependent P/Q-type Ca2+ channels.

Authors:  Yoshitsugu Uriu; Shigeki Kiyonaka; Takafumi Miki; Masakuni Yagi; Satoshi Akiyama; Emiko Mori; Akito Nakao; Aaron M Beedle; Kevin P Campbell; Minoru Wakamori; Yasuo Mori
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 2.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 3.  Designing highly active siRNAs for therapeutic applications.

Authors:  S Patrick Walton; Ming Wu; Joseph A Gredell; Christina Chan
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

Review 4.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

5.  Effect of target secondary structure on RNAi efficiency.

Authors:  Yu Shao; Chi Yu Chan; Anil Maliyekkel; Charles E Lawrence; Igor B Roninson; Ye Ding
Journal:  RNA       Date:  2007-08-07       Impact factor: 4.942

6.  Effects of template sequence and secondary structure on DNA-templated reactivity.

Authors:  Thomas M Snyder; Brian N Tse; David R Liu
Journal:  J Am Chem Soc       Date:  2008-01-08       Impact factor: 15.419

7.  Alternative splicing as a therapeutic target for human diseases.

Authors:  Kenneth J Dery; Veronica Gusti; Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Methods Mol Biol       Date:  2009

8.  Principles for Predicting RNA Secondary Structure Design Difficulty.

Authors:  Jeff Anderson-Lee; Eli Fisker; Vineet Kosaraju; Michelle Wu; Justin Kong; Jeehyung Lee; Minjae Lee; Mathew Zada; Adrien Treuille; Rhiju Das
Journal:  J Mol Biol       Date:  2016-02-17       Impact factor: 5.469

9.  Forward and robust selection of the most potent and noncellular toxic siRNAs from RNAi libraries.

Authors:  Zhen Li; Yves Fortin; Shi-Hsiang Shen
Journal:  Nucleic Acids Res       Date:  2008-11-29       Impact factor: 16.971

10.  Selection of hyperfunctional siRNAs with improved potency and specificity.

Authors:  Xiaowei Wang; Xiaohui Wang; Rajeev K Varma; Lesslie Beauchamp; Susan Magdaleno; Timothy J Sendera
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.